Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator’s choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) post-platinum therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Gillison, Maura L, Blumenschein, George, Fayette, Jerome, Guigay, Joel, Colevas, A Dimitrios, Licitra, Lisa, Harrington, Kevin J, Kasper, Stefan, Vokes, Everett E, Even, Caroline, Worden, Francis, Saba, Nabil F, Iglesias Docampo, Lara Carmen, Haddad, Robert, Rordorf, Tamara, Kiyota, Naomi, Tahara, Makoto, Jayaprakash, Vijayvel, Wei, Li, Ferris, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895496/
https://www.ncbi.nlm.nih.gov/pubmed/35641218
http://dx.doi.org/10.1093/oncolo/oyab036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895496/
https://www.ncbi.nlm.nih.gov/pubmed/35641218
http://dx.doi.org/10.1093/oncolo/oyab036

Ejemplares similares